Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Commun Biol. 2023 Jan 6;6(1):15. doi: 10.1038/s42003-022-04376-8.

Robert J Kimmerling^#¹, Mark M Stevens^#², Selim Olcum^#², Anthony Minnah^#², Madeleine Vacha^#², Rachel LaBella^#², Matthew Ferri², Steven C Wasserman², Juanita Fujii³, Zayna Shaheen³, Srividya Sundaresan³, Drew Ribadeneyra⁴, David S Jayabalan⁴, Sarita Agte^{5

6}, Adolfo Aleman^{5

6

7}, Joseph A Criscitiello⁸, Ruben Niesvizky⁴, Marlise R Luskin⁸, Samir Parekh^{5

6

9

10}, Cara A Rosenbaum⁴, Anobel Tamrazi¹¹, Clifford A Reid¹²

¹ Travera, Medford, MA, USA. rkimmerling@travera.com.
² Travera, Medford, MA, USA.
³ Department of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA, USA.
⁴ Weill Cornell Medicine, New York, NY, USA.
⁵ Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁷ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁹ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁰ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹¹ Division of Vascular and Interventional Radiology, Palo Alto Medical Foundation, Redwood City, CA, USA.
¹² Travera, Medford, MA, USA. creid@travera.com.

^# Contributed equally.

No abstract available

Publication types